Clinical Trial: Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Brief Summary: Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.
Detailed Summary:
Sponsor: Novartis
Current Primary Outcome: Changes in specific brain enzyme activity from baseline to week 13
Original Primary Outcome: Inhibition of targeted brain chemical
Current Secondary Outcome:
- Correlate changes in specific brain enzyme activity at week 13 to cognition and behavior
- Changes in levels of protein biomarkers in Alzheimer's disease and neurodegeneration from baseline to week 13
- Correlate changes in specific brain enzyme activity after 13 weeks treatment to changes in global functioning at 13 and 26 weeks
Original Secondary Outcome:
Information By: Novartis
Dates:
Date Received: February 28, 2005
Date Started: October 2003
Date Completion:
Last Updated: December 17, 2007
Last Verified: December 2007
